Romero-Steiner Sandra, Spear Willie, Brown Nekeidra, Holder Patricia, Hennessy Thomas, Gomez De Leon Patricia, Carlone George M
Division of Bacterial and Mycotic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Clin Diagn Lab Immunol. 2004 Jan;11(1):89-93. doi: 10.1128/cdli.11.1.89-93.2004.
We evaluated alamarBlue as a metabolic indicator in a standardized assay for the measurement of serum bactericidal activity (SBA) to Haemophilus influenzae type b (Hib) using sera containing natural and vaccine-induced anticapsular (polyribosylribitol phosphate) antibodies. SBA assays with a colorimetric and a fluorometric end point in the presence of alamarBlue were developed and compared to a standard SBA assay, where colony counts are performed to determine the titer (12). A colorimetric end point required a spectrophotometer, whereas a fluorometric end point required a fluorometer. Prevaccination sera (n = 27) and postvaccination sera (n = 13) were tested by all three methodologies, and the SBA titers obtained in the presence of alamarBlue were compared to those from the standard method. Both the colorimetric and the fluorometric SBA titers were significantly correlated (r = 0.87 and r = 0.95, respectively) with those of the standard assay (>/= 50% killing as the SBA titer end point), and titers were not significantly different when compared to those of the standard assay (P > 0.68). However, the fluorometric end point had superior performance and ease of titer determination compared to the colorimetric end point (95 versus 87% of SBA titers were within 2 dilutions of the standard titer). Hib SBA assays with alamarBlue are reproducible, faster (same-day assay), and easier to perform than the standardized assay, which requires manual or automated colony counts. These semiautomated methodologies result in increased sample throughput and collection of data in digital formats that can be exported to data analysis programs for determination of SBA titers.
我们使用含有天然和疫苗诱导的抗荚膜(多聚核糖基核糖醇磷酸)抗体的血清,在一项标准化试验中评估了alamarBlue作为代谢指标,用于测量血清对b型流感嗜血杆菌(Hib)的杀菌活性(SBA)。我们开发了在alamarBlue存在下具有比色和荧光终点的SBA试验,并将其与标准SBA试验进行比较,标准SBA试验通过菌落计数来确定效价(12)。比色终点需要一台分光光度计,而荧光终点需要一台荧光计。通过所有三种方法对疫苗接种前血清(n = 27)和疫苗接种后血清(n = 13)进行了检测,并将在alamarBlue存在下获得的SBA效价与标准方法获得的效价进行了比较。比色和荧光SBA效价与标准试验的效价均显著相关(分别为r = 0.87和r = 0.95,以≥50%杀菌作为SBA效价终点),与标准试验相比,效价无显著差异(P > 0.68)。然而,与比色终点相比,荧光终点具有更好的性能且效价测定更容易(95%对87%的SBA效价在标准效价的2倍稀释范围内)。与需要手动或自动菌落计数的标准化试验相比,使用alamarBlue的Hib SBA试验具有可重复性、速度更快(当天试验)且更易于操作。这些半自动化方法提高了样品通量,并以数字格式收集数据,可导出到数据分析程序中以确定SBA效价。